Literature DB >> 17224962

Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist.

Batoul Salama1, Jean-Jacques Gicquel, Patrice Lenoble, Paul Louis Dighiero.   

Abstract

CASE REPORT: To report a rare case of optic neuropathy in refractory neurosarcoidosis treated with tumour necrosis factor-alpha antagonist (infliximab) perfusion. A 41-year-old man with diabetes presented with an abrupt, painless, unilateral visual loss. Thoracic computed tomography disclosed mediastinal lymphadenopathy, and evidence from histopathology confirmed sarcoidosis. COMMENTS: Corticosteroids alone and with immunosuppressive agents failed to suppress the active disease. Alternative therapy of infliximab perfusions resulted in disease remission and relative visual improvement, and this treatment may warrant further clinical studies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17224962     DOI： 10.1139/i06-074

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN： 0008-4182            Impact factor:   1.882


  5 in total

1.  An ENU-induced mutation in the Mertk gene (Mertknmf12) leads to a slow form of retinal degeneration.

Authors:  Dennis M Maddox; Wanda L Hicks; Douglas Vollrath; Matthew M LaVail; Jürgen K Naggert; Patsy M Nishina
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-01       Impact factor: 4.799

2.  Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience.

Authors:  Yusuf Karabulut; Nuran Öz; Halise Hande Gezer; İrfan Esen; Mehmet Tuncay Duruöz
Journal:  Rheumatol Int       Date:  2022-08-25       Impact factor: 3.580

3.  Neurosarcoidosis: clinical review of a disorder with challenging inpatient presentations and diagnostic considerations.

Authors:  J Chad Hoyle; Courtney Jablonski; Herbert B Newton
Journal:  Neurohospitalist       Date:  2014-04

4.  A case series of refractory cutaneous sarcoidosis successfully treated with infliximab.

Authors:  Papapit Tuchinda; Matthew Bremmer; Anthony A Gaspari
Journal:  Dermatol Ther (Heidelb)       Date:  2012-07-26

Review 5.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.